Loading...
XLONAVCT
Market cap255mUSD
Jan 07, Last price  
56.00GBP
1D
-1.75%
1Q
8.74%
Jan 2017
-22.22%
Name

Avacta Group PLC

Chart & Performance

D1W1MN
XLON:AVCT chart
P/E
—
P/S
881.39
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
33.03%
Rev. gr., 5y
53.11%
Revenues
23m
+140.83%
19,000313,0004,000212,000466,000944,0002,067,0002,445,0003,130,0002,700,0003,180,0001,813,0002,165,0002,735,0002,763,0003,890,1042,144,0002,941,0009,653,00023,247,000
Net income
-25m
L-36.84%
-298,000-1,103,000-107,000-1,219,000-1,468,400-2,685,000-1,879,000-591,000-1,106,000-1,521,000-1,492,000-10,139,000-4,647,000-6,367,000-8,829,000-11,022,316-18,891,000-26,316,000-39,497,000-24,947,000
CFO
-15m
L-9.49%
-407,000-84,000-139,000-1,250,000-1,295,000-2,799,000-1,741,000-596,000-711,000-1,377,000-838,000-2,515,000-4,233,000-4,241,000-5,468,000-13,015,000-10,642,000-20,506,000-16,431,999-14,872,000
Earnings
Mar 18, 2025

Profile

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
URL
https://avacta.com/
IPO date
Sep 08, 2003
Employees
120
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122019‑072018‑072017‑072016‑072015‑07
Income
Revenues
23,247
140.83%
9,653
228.22%
Cost of revenue
46,293
30,041
Unusual Expense (Income)
NOPBT
(23,046)
(20,388)
NOPBT Margin
Operating Taxes
(2,370)
(2,102)
Tax Rate
NOPAT
(20,676)
(18,286)
Net income
(24,947)
-36.84%
(39,497)
50.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
398
8,868
BB yield
Debt
Debt current
17,559
59,190
Long-term debt
12,984
7,506
Deferred revenue
Other long-term liabilities
(1)
Net debt
9,837
21,939
Cash flow
Cash from operating activities
(14,872)
(16,432)
CAPEX
(1,220)
(594)
Cash from investing activities
(9,001)
(25,042)
Cash from financing activities
(1,298)
56,904
FCF
(17,435)
(22,622)
Balance
Cash
16,627
41,781
Long term investments
4,079
2,976
Excess cash
19,544
44,274
Stockholders' equity
(57,252)
(40,991)
Invested Capital
102,570
121,496
ROIC
ROCE
EV
Common stock shares outstanding
272,683
255,369
Price
Market cap
EV
EBITDA
(19,375)
(17,376)
EV/EBITDA
Interest
15,298
2,701
Interest/NOPBT